Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/13/2024 | Outperform → Mkt Perform | William Blair | ||
6/26/2024 | $392.00 | Overweight | Piper Sandler | |
6/24/2024 | $374.00 | Equal-Weight | Morgan Stanley | |
4/2/2024 | $470.00 → $342.00 | Buy → Neutral | BofA Securities | |
4/2/2024 | Buy → Neutral | BofA Securities | ||
3/22/2024 | Mkt Perform | Raymond James | ||
3/13/2024 | Buy → Hold | Argus | ||
3/6/2024 | $356.00 | Equal Weight | Barclays |
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
In collaboration with a leading researcher and professor at Harvard University, Humana's first-of-its-kind study found better access to primary care and narrowed racial and socio-economic disparities for those receiving care from senior-focused primary care organizations. Humana Inc. (NYSE:HUM), one of the nation's leading health and well-being companies, recently published a study on senior-focused primary care — a value-based care model that tailors the environment and services of clinical organizations to the unique needs of older adults. Published in Health Affairs, this study is the first of its size and scope in analyzing this type of organization. This joint study, conducted in par
MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is proud to shine a light on the powerful stories shared through the NeuroStar Voices Portal in recognition of Suicide Prevention Month. Launched last year, the portal has become a vital platform for individuals to share their journeys of battling depression and reclaiming their lives through NeuroStar Advanced Therapy. NeuroStar is also marking a key milestone, reaching halfway toward its goal of saving 3,325 lives with this transformative
Humana Inc. (NYSE:HUM), a leading health and well-being company, announced a new value-based kidney care program with Evergreen Nephrology designed to advance quality of care and help optimize health outcomes for people living with chronic kidney disease and end-stage kidney disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829112855/en/ Humana Medicare Advantage members who qualify for the program will now have access to a team of Evergreen professionals who work together in partnership with their nephrologist to provide individualized, whole-person care. Evergreen has nephrology practice partnerships in the following
8-K - HUMANA INC (0000049071) (Filer)
DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
8-K - Neuronetics, Inc. (0001227636) (Filer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - Neuronetics, Inc. (0001227636) (Issuer)
4 - HUMANA INC (0000049071) (Issuer)
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
SC 13G - Neuronetics, Inc. (0001227636) (Subject)
Builds On Ongoing Collaboration With Google Health To Develop Population Health Solutions And Address Healthcare Challenges
TD Cowen analyst Gary Taylor maintains Humana (NYSE:HUM) with a Buy and raises the price target from $396 to $407.
Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:HUM) with a Neutral and maintains $360 price target.
William Blair downgraded Neuronetics from Outperform to Mkt Perform
Piper Sandler initiated coverage of Humana with a rating of Overweight and set a new price target of $392.00
Morgan Stanley initiated coverage of Humana with a rating of Equal-Weight and set a new price target of $374.00
David Dintenfass to lead new centralized function focused on customer experience, sales and marketing Leading health insurer and health care services company Humana Inc. (NYSE:HUM) announced today that it has named David Dintenfass as President of Enterprise Growth. In this new role, Dintenfass will have responsibility for leading the company's growth plan with a primary focus on customer acquisition, retention, and experience. The creation of this position, and its emphasis on the customer and digital experience, will help Humana deliver on its long-term strategy and maximize long-term growth within the Medicare Advantage market. By 2030, one in five Americans is projected to be 65 years
Broussard, who reimagined senior-focused health care, announces he will step down after more than a decade of serving at the helm of the company Leading health insurer and health care services company Humana Inc. (NYSE:HUM) announced today it has named health care industry veteran Jim Rechtin as President and Chief Operating Officer of Humana Inc., effective January 8, 2024, as part of a long-planned CEO transition. He will report to Bruce Broussard, CEO, until the latter half of 2024 at which time Broussard will step down and Rechtin will assume the CEO role. Broussard joined Humana in 2011 and assumed the role of CEO in 2013. Over the last decade, he has led the company's transformati
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on October 25, 2024 to stockholders of record as of the close of business on September 30, 2024. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, mil
MALVERN, Pa. and TORONTO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTC:GBNHF) ("Greenbrook") today announced that they have entered into a definitive arrangement agreement (the "Definitive Agreement") in which Neuronetics will acquire all of the outstanding common shares of Greenbrook in an all-stock transaction. "This transaction brings together two of the leaders in the mental health space in the U.S., which will allow us to provide access to innovative care to patients suffering from mental health conditions. Leveraging the significant scale and capabilities of the two businesses, we can drive increased awareness of Neur
MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the second quarter of 2024. Second Quarter 2024 Highlights Second quarter 2024 revenue of $16.5 million, a 7% decrease as compared to the second quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4 million in the quarter, representing 50 systemsU.S. treatment session revenue decreased by 5% ve